Clinical trials: Continuous Renal Replacement Therapy
Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT)
Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT
Prismocitrate 18 is a continuous renal replacement therapy (CRRT) solution to be used as a renal replacement solution and as an anticoagulant to prevent blood clotting in the extracorporeal circuit.
- Conditions
- Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury (AKI)
- Trial name
- NCT05399537
- Testing
- Prismocitrate 18, PrisMax System Version 3.x with calcium line accessory
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Vantive Health LLC
Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT)
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
The purpose of this research is to determine if an investigational new drug solution called Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous renal replacement therapy (CRRT).
- Conditions
- Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury
- Trial name
- NCT02860130
- Testing
- Prismocitrate 18, No Anticoagulation
- Where
- 12 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Vantive Health LLC
Continuous Renal Replacement Therapy, Pulmonary Edema
C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19
The clinical trial will evaluate the short term and extended impact on on respiration, pulmonary function and cardiovascular function in C2Rx treatment verse Standard of Care (SOC) in critically ill adults with COVID-19…
- Conditions
- Continuous Renal Replacement Therapy, Pulmonary Edema, COVID-19
- Trial name
- NCT04537975
- Testing
- C2Rx, Standard of Care (SOC)
- Sponsor
- SeaStar Medical